Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

2.93USD
3:59pm EST
Change (% chg)

$0.02 (+0.69%)
Prev Close
$2.91
Open
$2.86
Day's High
$2.94
Day's Low
$2.86
Volume
246,423
Avg. Vol
157,799
52-wk High
$3.23
52-wk Low
$1.01

Chart for

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $248.03
Shares Outstanding(Mil.): 85.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 185.06 15.80
EPS (TTM): -- -- --
ROI: -- -10.84 12.07
ROE: -- -39.67 16.02

BRIEF-Catalyst Pharmaceuticals posts Q3 loss per share $0.05

* Catalyst Pharmaceuticals announces third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®

* Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome

Oct 31 2017

BRIEF-Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

* Catalyst Pharmaceuticals provides update on the status of its Firdapse development activities

Aug 30 2017

BRIEF-Catalyst Pharmaceuticals Q2 GAAP loss per share $0.05

* Catalyst pharmaceuticals announces second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-Catalyst Pharmaceuticals files for mixed shelf of up to $150 mln

* Catalyst Pharmaceuticals Inc files for mixed shelf of up to $150 million - SEC filing Source text for Eikon: (http://bit.ly/2tflLhO) Further company coverage:

Jul 12 2017

Competitors

Earnings vs. Estimates